If you have been reading about synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
=== Recreational === Benzydamine has been used recreationally. If taken in excess amounts, it acts as an atypical deliriant and CNS stimulant. Such use, particularly among teenagers, has been reported in Brazil, Poland, Romania, and Turkey.
== References == Endacott, G. B. Government and people in Hong Kong, 1841-1962 : a constitutional history. Hong Kong University Press. (1964) Wright, Arnold and H.A. Cartwright. Twentieth century impressions of Hong-kong, Shanghai, and other Treaty Ports of China. London: Lloyd's Greater Britain Pub. Co. (1908)
== In biology == The best-studied 2-Carboxy-D-arabinitol-1-phosphate phosphatase is the enzyme that inactivates the RuBisCO inhibitor 2-carboxy-D-arabinitol-1-phosphate (CA1P). When light levels are high, the inactivation occurs after CA1P has been released from RuBisCO by RuBisCO activase. As CA1P is present in many but not all plants, CA1P-mediated regulation of RuBisCO is not universal for all photosynthetic life. Amino acid sequences of the CA1Pase enzymes from wheat, French bean, tobacco, and Arabidopsis thaliana reveal that the enzymes contain 2 different domains, indicating that it is a multifunctional enzyme. CA1Pase enzyme activity varies between different species due to their regulation by different redox-active compounds, such as glutathione. However, it is yet to be determined whether this process occurs in vivo. Wheat CA1Pase heterologously expressed in E. coli is also able to dephosphorylate the RuBisCO inhibitor D-glycero-2,3-diulose-1,5-bisphosphate.
== History == Pyridoxine was discovered in 1934, isolated in 1938, and first made in 1939. It is on the World Health Organization's List of Essential Medicines. Pyridoxine is available both as a generic medication and over the counter product. Foods, such as breakfast cereal have pyridoxine added in some countries.
== External links == Granulocyte+Colony-Stimulating+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P09919 (Granulocyte colony-stimulating factor) at the PDBe-KB.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}{\text{triglyceride}}+{\ce {H2O}}&\longrightarrow {\text{fatty acid}}+{\text{diacylglycerol}}\\[4pt]{\text{diacylglycerol}}+{\ce {H2O}}&\longrightarrow {\text{fatty acid}}+{\text{monacylglycerol}}\\[4pt]{\text{monacylglycerol}}+{\ce {H2O}}&\longrightarrow {\text{fatty acid}}+{\text{glycerol}}\end{aligned}}}
=== Detection of phytopathogens === The agricultural industry is constantly striving to produce plant propagules or seedlings that are free of pathogens in order to prevent economic losses and safeguard health. Systems have been developed that allow detection of small amounts of the DNA of Phytophthora ramorum, an oomycete that kills oaks and other species, mixed in with the DNA of the host plant. Discrimination between the DNA of the pathogen and the plant is based on the amplification of ITS sequences, spacers located in ribosomal RNA gene's coding area, which are characteristic for each taxon. Field-based versions of this technique have also been developed for identifying the same pathogen.
Harry Emerson. For services to the community in Stockton-on-Tees, Cleveland. Elizabeth Margaret Evans. For services to the community, particularly Disabled People, in Llanelli, Dyfed. Shirley Everett, Newsvendor. For services to the community in Westminster, London. Doris Mabel Eves. For services to the Citizens' Advice Bureau in Farnborough, Hampshire. George Fitton Exley, Honorary Secretary, Scarborough Lifeboat Station. For services to the Royal National Lifeboat Institution. Ellen Branker Farmer, President, Old Paisley Society. For services to Conservation. Margaret Winifred Farmer. For services to the Royal British Legion in Sevenoaks, Kent. Eric Arnold Faux. For services to disabled people in Birmingham Valerie Ann Fea, lately Executive Secretary, the School Library Association. For services to Librananship and to Young People. Heather Duncan Findlay, Local Officer 2, the Benefits Agency, Department of Social Security. Nina Mary Fineron, lately Typist, Department of Social Security. Isabel H. Finlay, lately Chiropodist, Glasgow. For services to Health Care. Millar Henry Finlay, Divisional Officer, (Special Constabulary), Flintshire Division, North Wales Police. For services to the Police. Olwen Finlay. For services to Physiotherapy. Evelyn May Fisher. For services to Netball in Coventry. Myra Caroline Fisher. For services to the community in Paulsgrove, Portsmouth, Hampshire. Bernard Joseph Fitzsimmons. For public service. Michael Robert Flegg, Catering Manager, Nottingham City Hospital. For services to Health Care. Iris Mary Fletcher.
Powys covers the historic counties of Montgomeryshire and Radnorshire, most of Brecknockshire, and part of historic Denbighshire. With an area of about 2,000 square miles (5,200 km2), it is now the largest administrative area in Wales by land and area (Dyfed was until 1996 before several former counties created by the Local Government Act 1972 were abolished). It is bounded to the north by Gwynedd, Denbighshire and Wrexham County Borough; to the west by Ceredigion and Carmarthenshire; to the east by Shropshire and Herefordshire; and to the south by Rhondda Cynon Taf, Merthyr Tydfil County Borough, Caerphilly County Borough, Blaenau Gwent, Monmouthshire and Neath Port Talbot. The largest towns are Newtown, Ystradgynlais, Brecon, Welshpool, Llandrindod Wells and Knighton. Powys has the lowest population density of all the principal areas of Wales. Most of Powys is mountainous, and most roads and railways are relatively slow. Just under a third of the residents have Welsh linguistic skills: Welsh speakers are concentrated mainly in the rural areas both in and around Machynlleth, Llanfyllin and Llanrhaeadr-ym-Mochnant (where William Morgan first translated the whole Bible into Welsh in 1588) in Montgomeryshire, and the industrial area of Ystradgynlais in the southwest of Brecknockshire. In Radnorshire, the language survived into the 20th century west of Rhayader with a few native speakers from Nantmel parish surviving into the 20th century too.
=== Kröhnke pyridine synthesis === In the Kröhnke pyridine synthesis, an N-pyridine-substituted methyl ketone is used as the reactant. This compound enters the keto-enol equilibrium and reacts with an enone via a Michael addition. A 1,5-dicarbonyl compound is formed, one carbonyl group of which is replaced by ammonia (or a synthesis equivalent) to form an imine. This intermediate subsequently cyclizes to give a pyridine. The reaction is named after Fritz Kröhnke, who developed it for the preparation of 2,4,6-triarylpyridines and published it in 1961.
Sources: en.wikipedia.org
==== Structured breast prosthesis ==== The fourth category of prosthetic-breast technology is the structured breast-prosthesis, which was approved for breast surgery by the Food and Drug Administration in the U.S. and by Health Canada in Canada in 2014. As a medical device, the structured prosthetic-breast incorporates the technologies of saline-solution and of silicone-gel to achieve anatomical function and aesthetic symmetry. Technologically, the internal structure of the breast prosthesis is composed of three, nested shells (made of silicone rubber) that support the upper half of the breast hemisphere; the two spaces between the three nested shells is filled with saline solution. To implant a structured breast prosthesis, the plastic surgeon emplaces the folded, empty prosthetic breast into the implant-socket, then fills the prosthetic breast with saline solution, and afterwards sutures shut the insertion incision.
==== Structure ==== The myophosphorylase structure consists of 842 amino acids. The molecular weight of the unprocessed precursor is 97 kDa. The three-dimensional structure has been determined for this protein. The interactions of several amino acids in myophosphorylase's structure are known. Ser-14 is modified by phosphorylase kinase during activation of the enzyme. Lys-680 is involved in binding the pyridoxal phosphate, which is the active form of vitamin B6, a cofactor required by myophosphorylase. By similarity, other sites have been estimated: Tyr-76 binds AMP, Cys-109 and Cys-143 are involved in subunit association, and Tyr-156 may be involved in allosteric control.
== External links == Jewish State.com Zionism, News, Links Israeli Jewish scene from ynetnews Israel as a Jewish state from the Jerusalem Center for Public Affairs 'Israel a Jewish state first', says former High Court Justice Dalia Dorner
Often, the patient consumes about 3–4 times the RDA's specification. Toxicity of vitamin A is believed to be associated with the methods of increasing vitamin A in the body, such as food modification, fortification, and supplementation, all of which are used to combat vitamin A deficiency. Toxicity is classified into two categories: acute and chronic. The former occurs a few hours or days after ingestion of a large amount of vitamin A. Chronic toxicity takes place when about 4,000 IU/kg or more of vitamin A is consumed for a long time. Symptoms of both include nausea, blurred vision, fatigue, weight loss, and menstrual abnormalities. Excess vitamin A is suspected to be a contributor to osteoporosis. This seems to happen at much lower doses than those required to induce acute intoxication. Only preformed vitamin A can cause these problems because the conversion of carotenoids or retinyl esters into vitamin A is downregulated when physiological requirements are met; but excessive uptake of carotenoids can cause carotenosis. Excess preformed vitamin A during early pregnancy is associated with a significant increase in birth defects. These defects may be severe, even life-threatening. Even twice the daily recommended amount can cause severe birth defects. The FDA recommends that pregnant women get their vitamin A from foods containing beta carotene and that they ensure that they consume no more than 5,000 IU of preformed vitamin A (if any) per day.
The main foreign policy goal of Franz Joseph had been the unification of Germany under the House of Habsburg. This was justified on grounds of precedence; from 1452 to the end of the Holy Roman Empire in 1806, with only one brief period of interruption under the House of Wittelsbach, the Habsburgs had generally held the German crown. However, Franz Joseph's desire to retain the non-German territories of the Habsburg Austrian Empire in the event of German unification proved problematic. Two factions quickly developed: a party of German intellectuals favouring a Greater Germany (Großdeutschland) under the House of Habsburg; the other favouring a Lesser Germany (Kleindeutschland). The Greater Germans favoured the inclusion of Austria in a new all-German state on the grounds that Austria had always been a part of Germanic empires, that it was the leading power of the German Confederation, and that it would be absurd to exclude eight million Austrian Germans from an all-German nation state. The champions of a lesser Germany argued against the inclusion of Austria on the grounds that it was a multi-nation state, not a German one, and that its inclusion would bring millions of non-Germans into the German nation state. If Greater Germany were to prevail, the crown would necessarily have to go to Franz Joseph, who had no desire to cede it in the first place to anyone else.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.